Pliant Therapeutics to Present at 37 th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO — December 27, 2018 — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that Bernard Coulie, M.D., Ph.D., president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference. Dr. Coulie’s presentation will take place at 9:00 a.m. PST on Wednesday, January 9, 2019, at the Westin St. Francis in San Francisco, Calif.

About Pliant Therapeutics

Pliant Therapeutics is a biotechnology company unraveling and targeting the key biological pathways driving fibrosis. By leveraging its powerful product discovery engine, Pliant’s mission is to develop novel therapeutics that seek to halt progression of fibrotic diseases, ultimately preserving organ function. Founded by a group of seasoned experts in fibrosis biology, medicinal chemistry, translational medicine and clinical development, Pliant’s lead product candidate PLN-74809 is being evaluated in a Phase 1 study to enable further development in idiopathic pulmonary fibrosis and other indications. Additional programs are expected to advance into the clinic in 2019. For more information, please visit www.pliantrx.com.

Media Contact:
Cambria Fuqua
Canale Communications
(619) 849-5390
cambria@canalecomm.com